Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
-
- STATUS
- Recruiting
Summary
You are being asked to take part in this study because you have been diagnosed with major depressive disorder (depression). Brexpiprazole is a medication being studied as a possible treatment for adjunctive treatment for Major Depressive Disorder (MDD). It was first approved in the United States (10 July 2015) for the treatment of schizophrenia and as an adjunctive therapy (add-on therapy) to antidepressants for the treatment of major depressive disorder.
The reason for this study is to find out about the potential benefits, tolerability and safety of brexpiprazole as an adjunctive therapy to your current antidepressant.
Description
If you decide to join, you will be asked to sign this consent form. By signing this form, you agree to follow the instructions given by the research staff during the study. Once you sign the form, the study doctor and staff will review your medical records, check some details with you and perform some tests to confirm if you are appropriate for the study. These tests can take up to 42 days to complete.
You will be notified by the study staff if you are approved by the study doctor to participate.
If you are confirmed appropriate for the study, you will have the first treatment visit and be given your assigned study medication to begin taking.
The study is broken into 3 phases. Phase A lasts for 6-8 weeks with a total of 9 visits and at the end of this period depending upon how you are doing, you might continue in the next phase.
If you meet certain criteria at the end of phase A, you may be eligible to continue in 12 weeks long phase B which includes a total of 12 visits.
Depending on your response to the study drug and if you continue to meet study criteria at the end of phase B, you may be eligible to participate in the next 26 weeks long phase C of the study with 9 visits to the clinic and a follow up visit over the phone.
If you cannot tolerate the dose of study medication (or matching placebo) you are given, you will be discontinued from the study.
FAQ
Details
| Condition | depression |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX6083 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.